Northern Trust Corp Ardelyx, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Ardelyx, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 2,100,533 shares of ARDX stock, worth $10.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,100,533
Previous 2,075,037 1.23%
Holding current value
$10.4 Million
Previous $15.4 Million 5.88%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$5.28 - $7.57 $134,618 - $193,004
25,496 Added 1.23%
2,100,533 $14.5 Million
Q2 2024

Aug 14, 2024
SELL
$5.89 - $9.31 $435,111 - $687,757
-73,873 Reduced 3.44%
2,075,037 $15.4 Million
Q1 2024

May 14, 2024
SELL
$6.05 - $9.74 $235,393 - $378,963
-38,908 Reduced 1.78%
2,148,910 $15.7 Million
Q4 2023

Feb 13, 2024
BUY
$3.29 - $6.64 $762,125 - $1.54 Million
231,649 Added 11.84%
2,187,818 $13.6 Million
Q3 2023

Nov 13, 2023
BUY
$3.3 - $4.83 $14,470 - $21,179
4,385 Added 0.22%
1,956,169 $7.98 Million
Q2 2023

Aug 11, 2023
BUY
$3.23 - $4.95 $4.78 Million - $7.33 Million
1,480,747 Added 314.36%
1,951,784 $6.62 Million
Q1 2023

May 15, 2023
BUY
$2.68 - $4.79 $272,221 - $486,544
101,575 Added 27.49%
471,037 $2.26 Million
Q4 2022

Feb 13, 2023
BUY
$1.22 - $2.85 $123,123 - $287,624
100,921 Added 37.58%
369,462 $1.05 Million
Q3 2022

Nov 14, 2022
BUY
$0.59 - $1.44 $42,388 - $103,456
71,845 Added 36.53%
268,541 $320,000
Q2 2022

Aug 12, 2022
SELL
$0.51 - $1.17 $321,513 - $737,590
-630,419 Reduced 76.22%
196,696 $116,000
Q1 2022

May 13, 2022
BUY
$0.65 - $1.18 $4,218 - $7,658
6,490 Added 0.79%
827,115 $885,000
Q4 2021

Feb 08, 2022
SELL
$0.86 - $1.7 $19,316 - $38,183
-22,461 Reduced 2.66%
820,625 $903,000
Q3 2021

Nov 15, 2021
SELL
$1.27 - $8.17 $28,181 - $181,292
-22,190 Reduced 2.56%
843,086 $1.11 Million
Q2 2021

Aug 13, 2021
BUY
$6.55 - $8.98 $264,770 - $362,998
40,423 Added 4.9%
865,276 $6.56 Million
Q1 2021

May 12, 2021
SELL
$6.1 - $7.69 $218,068 - $274,909
-35,749 Reduced 4.15%
824,853 $5.46 Million
Q4 2020

Feb 11, 2021
SELL
$5.05 - $7.1 $35,521 - $49,941
-7,034 Reduced 0.81%
860,602 $5.57 Million
Q3 2020

Nov 16, 2020
SELL
$5.25 - $7.08 $322,166 - $434,464
-61,365 Reduced 6.61%
867,636 $4.56 Million
Q2 2020

Aug 14, 2020
BUY
$5.37 - $8.11 $959,441 - $1.45 Million
178,667 Added 23.81%
929,001 $6.43 Million
Q1 2020

May 14, 2020
BUY
$4.35 - $8.79 $635,856 - $1.28 Million
146,174 Added 24.19%
750,334 $4.27 Million
Q4 2019

Feb 14, 2020
BUY
$4.23 - $8.29 $216,808 - $424,903
51,255 Added 9.27%
604,160 $4.53 Million
Q3 2019

Nov 13, 2019
BUY
$2.15 - $6.28 $48,342 - $141,205
22,485 Added 4.24%
552,905 $2.6 Million
Q2 2019

Aug 13, 2019
BUY
$2.49 - $3.73 $35,644 - $53,394
14,315 Added 2.77%
530,420 $1.43 Million
Q1 2019

May 13, 2019
BUY
$1.88 - $3.35 $2,195 - $3,912
1,168 Added 0.23%
516,105 $1.45 Million
Q4 2018

Feb 12, 2019
SELL
$1.66 - $4.16 $1,092 - $2,737
-658 Reduced 0.13%
514,937 $922,000
Q3 2018

Nov 14, 2018
BUY
$3.75 - $4.65 $386,988 - $479,866
103,197 Added 25.02%
515,595 $2.24 Million
Q2 2018

Sep 18, 2018
BUY
$3.7 - $5.8 $9,124 - $14,302
2,466 Added 0.6%
412,398 $1.53 Million
Q2 2018

Aug 14, 2018
BUY
$3.7 - $5.8 $141,850 - $222,360
38,338 Added 10.32%
409,932 $1.52 Million
Q1 2018

May 09, 2018
SELL
$5.05 - $7.9 $10,599 - $16,582
-2,099 Reduced 0.56%
371,594 $1.88 Million
Q4 2017

Feb 14, 2018
SELL
$4.85 - $7.8 $70,708 - $113,716
-14,579 Reduced 3.75%
373,693 $2.47 Million
Q3 2017

Nov 13, 2017
BUY
$4.35 - $5.7 $1.69 Million - $2.21 Million
388,272
388,272 $2.17 Million

Others Institutions Holding ARDX

# of Institutions
220
Shares Held
141M
Call Options Held
1.08M
Put Options Held
2M
View Full List

About ARDELYX, INC.

ARDX Quotes by TradingView
  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $769M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email